Simple ‘Gut Reset’ Procedure May Prevent Weight Rebound After GLP-1 Drug Discontinuation

An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining the pounds they shed, according to a study to be presented at Digestive Disease Week® (DDW) 2026.

Nearly one in five adults with obesity has taken a glucagon-like peptide-1 (GLP-1), and many experience weight rebound once they stop the drug, regaining their lost weight within 18 months on average.

The study presents the first blinded, randomized, sham-controlled evidence that the procedure known as duodenal mucosal resurfacing may offer a safe, effective and lasting way to maintain drug-free weight loss following GLP-1 discontinuation.

“As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to accept a drug long-term,” said lead author Shelby Sullivan, MD, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and professor of medicine, Dartmouth Geisel School of Medicine. “But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost. Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need. These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance.”

Duodenal mucosal resurfacing is an investigational endoscopic procedure that uses targeted heat to ablate (burn) the unhealthy inner mucosal lining of the duodenum, the upper part of the small intestine that sits just below the stomach. The REMAIN-1 trial is testing whether duodenal mucosal resurfacing, which stimulates the growth of fresh, healthy tissue, can result in a sustained metabolic reset.

The findings are based on the first group of trial participants, who now have six months of follow-up data.

Duodenal mucosal resurfacing aims to reset individuals’ metabolism to their new post-GLP-1 weight, leading to sustained effects.

How Duodenal Mucosal Resurfacing Works

Duodenal mucosal resurfacing (DMR) is a minimally invasive endoscopic procedure designed to treat the duodenum, the first part of the small intestine. The procedure involves using a specialized catheter to deliver controlled thermal energy to the duodenal mucosa, ablating the unhealthy lining. This process stimulates the body’s natural healing response, promoting the regeneration of a healthier mucosal layer.

By resetting the duodenal mucosa, DMR may improve metabolic function, including glucose homeostasis and insulin sensitivity, which are often disrupted in obesity and type 2 diabetes. The procedure does not involve cutting or removing tissue; instead, it focuses on renewing the surface layer to restore normal function.

Clinical Evidence Supporting DMR for Weight-Loss Maintenance

The REMAIN-1 trial, a randomized, sham-controlled study, is evaluating the safety and efficacy of DMR in patients who have achieved weight loss with GLP-1 receptor agonists. Early results from the trial show that participants who underwent DMR maintained their weight loss and metabolic improvements after discontinuing GLP-1 medications, whereas those in the sham group experienced significant weight regain.

At six months follow-up, the DMR group demonstrated sustained weight loss maintenance and improved glycemic control compared to the sham group. These findings suggest that DMR may help prevent the metabolic rebound commonly seen after stopping GLP-1 therapy.

The procedure’s ability to promote mucosal regeneration addresses a key mechanism behind weight regain: the gut’s role in regulating metabolism and appetite. By restoring a healthy duodenal environment, DMR may help maintain the metabolic benefits achieved during GLP-1 therapy.

Potential Benefits and Considerations

Duodenal mucosal resurfacing offers several potential advantages for individuals seeking to maintain weight loss after GLP-1 discontinuation:

• Minimally invasive outpatient procedure with no incisions or sutures
• Targets the root cause of metabolic dysfunction in the gut
• May provide lasting effects without the need for ongoing medication
• Reversible and repeatable if needed

As an investigational procedure, DMR is not yet widely available and is currently being studied in clinical trials. Patients interested in DMR should consult with their healthcare provider about eligibility and ongoing research opportunities.

Common side effects reported in trials include mild to moderate abdominal discomfort, nausea, and transient elevations in liver enzymes, which typically resolve within a few days. Serious adverse events are rare but may include pancreatitis or perforation, underscoring the importance of the procedure being performed by trained specialists in a controlled setting.

The Future of Weight-Loss Maintenance

As research continues, duodenal mucosal resurfacing represents a promising avenue for addressing the challenge of weight rebound after GLP-1 therapy. If larger trials confirm these early results, DMR could become a valuable tool in the long-term management of obesity and related metabolic conditions.

For now, individuals using GLP-1 medications should discuss their long-term weight-loss maintenance plans with their healthcare provider, considering all available options, including lifestyle modifications, behavioral support, and emerging procedures like DMR.

The ongoing REMAIN-1 trial and similar studies will provide critical data on the safety, efficacy, and durability of duodenal mucosal resurfacing, helping to shape future guidelines for obesity treatment.

Simple ‘Gut Reset’ Procedure May Prevent Weight Rebound After GLP-1 Drug Discontinuation

An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining the pounds they shed, according to a study to be presented at Digestive Disease Week® (DDW) 2026.

Nearly one in five adults with obesity has taken a glucagon-like peptide-1 (GLP-1), and many experience weight rebound once they stop the drug, regaining their lost weight within 18 months on average.

The study presents the first blinded, randomized, sham-controlled evidence that the procedure known as duodenal mucosal resurfacing may offer a safe, effective and lasting way to maintain drug-free weight loss following GLP-1 discontinuation.

“As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term,” said lead author Shelby Sullivan, MD, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and professor of medicine, Dartmouth Geisel School of Medicine. “But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost. Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need. These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance.”

Duodenal mucosal resurfacing is an investigational endoscopic procedure that uses targeted heat to ablate (burn) the unhealthy inner mucosal lining of the duodenum, the upper part of the small intestine that sits just below the stomach. The REMAIN-1 trial is testing whether duodenal mucosal resurfacing, which stimulates the growth of new, healthy tissue, can result in a sustained metabolic reset.

The findings are based on the first group of trial participants, who now have six months of follow-up data.

Duodenal mucosal resurfacing aims to reset individuals’ metabolism to their new post-GLP-1 weight, leading to sustained effects.

How Duodenal Mucosal Resurfacing Works

Duodenal mucosal resurfacing (DMR) is a minimally invasive endoscopic procedure designed to treat the duodenum, the first part of the small intestine. The procedure involves using a specialized catheter to deliver controlled thermal energy to the duodenal mucosa, ablating the unhealthy lining. This process stimulates the body’s natural healing response, promoting the regeneration of a healthier mucosal layer.

By resetting the duodenal mucosa, DMR may improve metabolic function, including glucose homeostasis and insulin sensitivity, which are often disrupted in obesity and type 2 diabetes. The procedure does not involve cutting or removing tissue; instead, it focuses on renewing the surface layer to restore normal function.

Clinical Evidence Supporting DMR for Weight-Loss Maintenance

The REMAIN-1 trial, a randomized, sham-controlled study, is evaluating the safety and efficacy of DMR in patients who have achieved weight loss with GLP-1 receptor agonists. Early results from the trial show that participants who underwent DMR maintained their weight loss and metabolic improvements after discontinuing GLP-1 medications, whereas those in the sham group experienced significant weight regain.

At six months follow-up, the DMR group demonstrated sustained weight loss maintenance and improved glycemic control compared to the sham group. These findings suggest that DMR may help prevent the metabolic rebound commonly seen after stopping GLP-1 therapy.

The procedure’s ability to promote mucosal regeneration addresses a key mechanism behind weight regain: the gut’s role in regulating metabolism and appetite. By restoring a healthy duodenal environment, DMR may help maintain the metabolic benefits achieved during GLP-1 therapy.

Potential Benefits and Considerations

Duodenal mucosal resurfacing offers several potential advantages for individuals seeking to maintain weight loss after GLP-1 discontinuation:

• Minimally invasive outpatient procedure with no incisions or sutures
• Targets the root cause of metabolic dysfunction in the gut
• May provide lasting effects without the need for ongoing medication
• Reversible and repeatable if needed

As an investigational procedure, DMR is not yet widely available and is currently being studied in clinical trials. Patients interested in DMR should consult with their healthcare provider about eligibility and ongoing research opportunities.

Common side effects reported in trials include mild to moderate abdominal discomfort, nausea, and transient elevations in liver enzymes, which typically resolve within a few days. Serious adverse events are rare but may include pancreatitis or perforation, underscoring the importance of the procedure being performed by trained specialists in a controlled setting.

The Future of Weight-Loss Maintenance

As research continues, duodenal mucosal resurfacing represents a promising avenue for addressing the challenge of weight rebound after GLP-1 therapy. If larger trials confirm these early results, DMR could become a valuable tool in the long-term management of obesity and related metabolic conditions.

For now, individuals using GLP-1 medications should discuss their long-term weight-loss maintenance plans with their healthcare provider, considering all available options, including lifestyle modifications, behavioral support, and emerging procedures like DMR.

The ongoing REMAIN-1 trial and similar studies will provide critical data on the safety, efficacy, and durability of duodenal mucosal resurfacing, helping to shape future guidelines for obesity treatment.